Ramesh K Ramanathan1,2,3, Glen J Weiss1,3, Richard G Posner3, N V Rajeshkumar4,5, Gayle Jameson1, Meraj Aziz3, Antje Hoering5, Vanessa Bolejack6, Anirban Maitra4,7, Monica Fulk1, Edward C Stites3, William S Hlavacek3, Zoran Gatalica8, Joanne Xiu8, Manuel Hidalgo9,10, Daniel D Von Hoff1,3, Michael T Barrett2,3. 1. Honor Health Research Institute, Scottsdale, AZ, USA. 2. Mayo Clinic Cancer Center, Phoenix, AZ, USA. 3. Translational Genomics Research Institute, Phoenix, AZ, USA. 4. Department of Oncology and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Human Therapeutics Division, Intrexon Corporation, Germantown, MD, USA. 6. Cancer Research And Biostatistics(CRAB), Seattle, WA, USA. 7. Sheikh Ahmed Pancreatic Cancer Research Center, UT MD Anderson Cancer Center, Houston, TX, USA. 8. Caris Life Sciences, Phoenix, AZ, USA. 9. Beth Israel Deaconess Medical Center, Boston, MA, USA. 10. Centro Nacional de Investigaciones Oncológicas and Hospital de Madrid, Madrid, Spain.
Abstract
BACKGROUND: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies. METHODS: Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC. The study required 35 evaluable patients (power of 86%) for detecting a true 1-year survival rate of >20%. RESULTS: A tumor biopsy was performed in 48 of 49 accrued patients. Study therapy was not given (n=13) either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after biopsy (n=5). The demographics of evaluable patients (n=35) are male/female (59%/41%), with age range 34-78 years (median 63 years). Patients had 1-6 prior regimens (median of 2). The most common IHC targets were topoisomerase 1 or 2, thymidylate synthase, excision repair cross-complementation group 1 protein (ERCC1), and osteonectin secreted protein acidic and rich in cysteine (SPARC). Commercially available treatment regimens prescribed included FOLFIRI, FOLFOX, irinotecan, and doxorubicin. The response (RECIST) was 9%, the median survival was 5.6 months (94% CI, 3.8-8.2), and the 1-year survival was 20% (95% CI, 7-33%). CONCLUSIONS: In all patients, IHC assays resulted in identification of at least two targets for therapy and a non-cross resistant regimen could be prescribed for therapy with evidence of some benefit. An IHC based treatment strategy is feasible and needs validation in larger studies.
BACKGROUND: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies. METHODS: Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC. The study required 35 evaluable patients (power of 86%) for detecting a true 1-year survival rate of >20%. RESULTS: A tumor biopsy was performed in 48 of 49 accrued patients. Study therapy was not given (n=13) either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after biopsy (n=5). The demographics of evaluable patients (n=35) are male/female (59%/41%), with age range 34-78 years (median 63 years). Patients had 1-6 prior regimens (median of 2). The most common IHC targets were topoisomerase 1 or 2, thymidylate synthase, excision repair cross-complementation group 1 protein (ERCC1), and osteonectin secreted protein acidic and rich in cysteine (SPARC). Commercially available treatment regimens prescribed included FOLFIRI, FOLFOX, irinotecan, and doxorubicin. The response (RECIST) was 9%, the median survival was 5.6 months (94% CI, 3.8-8.2), and the 1-year survival was 20% (95% CI, 7-33%). CONCLUSIONS: In all patients, IHC assays resulted in identification of at least two targets for therapy and a non-cross resistant regimen could be prescribed for therapy with evidence of some benefit. An IHC based treatment strategy is feasible and needs validation in larger studies.
Authors: Peter J Hosein; Gilberto de Lima Lopes; Vitor H Pastorini; Christina Gomez; Jessica Macintyre; Gloria Zayas; Isildinha Reis; Alberto J Montero; Jaime R Merchan; Caio M Rocha Lima Journal: Am J Clin Oncol Date: 2013-04 Impact factor: 2.339
Authors: Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux Journal: N Engl J Med Date: 2011-05-12 Impact factor: 91.245
Authors: Davendra P S Sohal; Pamela B Mangu; Alok A Khorana; Manish A Shah; Philip A Philip; Eileen M O'Reilly; Hope E Uronis; Ramesh K Ramanathan; Christopher H Crane; Anitra Engebretson; Joseph T Ruggiero; Mehmet S Copur; Michelle Lau; Susan Urba; Daniel Laheru Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Ying Chuan Hu; Richard A Komorowski; Shannon Graewin; Galen Hostetter; Olli-P Kallioniemi; Henry A Pitt; Steven A Ahrendt Journal: Clin Cancer Res Date: 2003-09-15 Impact factor: 12.531
Authors: Michael S Braun; Susan D Richman; Philip Quirke; Catherine Daly; Julian W Adlard; Faye Elliott; Jennifer H Barrett; Peter Selby; Angela M Meade; Richard J Stephens; Mahesh K B Parmar; Matthew T Seymour Journal: J Clin Oncol Date: 2008-06-01 Impact factor: 44.544
Authors: Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler Journal: N Engl J Med Date: 2013-10-16 Impact factor: 91.245